Focused on rare disease therapies, this biotech firm reported a notable insider sale amid a year of substantial share price ...

Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the 10 Stocks With Monster Returns. Travere Therapeutics grew its share ...

Notably, investors poured funds into industries with promising growth prospects, namely semiconductor and quantum computing, ...

The trial compares sparsentan, an oral pill developed by Travere Therapeutics, Inc., with the standard angiotensin receptor blocker irbesartan. Both drugs aim to slow kidney damage in focal segmental ...

Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug and medical ...

Full FDA approval covers proteinuria reduction in FSGS without nephrotic syndrome, a defined clinical subset differentiated ...

Regeneron and Telix announced a strategic radiopharma collaboration worth up to $4.3 billion. Daiichi Sankyo entered a $1.55 ...

The latest health news includes calls for transparency in FDA's accelerated drug approvals, expanded use of Travere's kidney drug, Roche's new study for gene therapy, and Hetero's global drug rollout ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...

Recent advancements in health news highlight the FDA's approval of Travere's drug for a rare kidney disease, new AI tools for ...

Travere Therapeutics’ sparsentan receives US FDA nod to treat focal segmental glomerulosclerosis; the first and only approved medicine for FSGS: San Diego Wednesday, April 15, 2 ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.